Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
about
Sunitinib in the treatment of metastatic renal cell carcinomaIncidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patientsRenal cell carcinoma.Renal cell cancer: overview of the current therapeutic landscape.Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer.Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer.Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma.C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.Low-value practices in oncology contributing to financial toxicity.Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.Inflammatory fibroblasts in cancer.Retroperitoneal Lymphadenectomy in High-Risk Non-Metastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.Adjuvant therapy for high-risk localized kidney cancer- emerging evidence and future clinical trials.Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity.miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan.Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma.Sunitinib in kidney cancer: 10 years of experience and development.Pharmacotherapy for treating metastatic clear cell renal cell carcinoma.Targeted therapies for renal cell carcinoma.Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinomaAsymptomatic Pancreatic Metastasis from Renal Cell Carcinoma Diagnosed 21 Years after Nephrectomy.The world of targeted therapies in kidney cancers: pitfalls, tips and tricks.Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.European Society for Medical Oncology Copenhagen update: potential practice-changing findingsAdjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial.Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR.ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics.Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study.Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis.Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?
P2860
Q28072057-DAB39EAF-9403-49D5-9B7B-5FF052E7B883Q28079328-183041DD-B451-49BD-9B19-ED931E30D3C3Q30235364-D556BF7C-B781-48CD-8013-2D55C13BF7FBQ30248354-D7541620-06B5-41C7-99A5-B1ECD25095C6Q36291489-7B016F82-7436-4033-A492-0B0B420CB5CAQ36913538-AEC6C9FF-2DD2-4F2D-8FBB-356819638A6DQ37411781-FB1E3447-82B1-43C1-813F-493C2A57159DQ37532265-68D7E78C-B9E5-44AC-BF72-2236C6DDC8F5Q37564471-6DA8FB83-3A6B-429E-989C-23850CEC16A6Q37595980-3D3E8901-9A55-4BF0-9AE5-A7C1B4031BECQ37720714-EEDCCFC9-0022-4CB4-A3C7-80BB6D676298Q38379672-BB330C33-8754-4916-A2EA-8153F0D6FE36Q38385722-9A546409-82F3-44C9-9ECA-F74640AAD9B9Q38412911-9BFF56F6-3CC4-4833-8101-F9609BF03BDFQ38654160-2D3DD402-E87F-45B1-8C0E-699166B19C6EQ38672966-DECC3BB2-6E37-4377-A9A7-D42CD4CCA9A1Q38673512-5CC33CFF-F5F3-4F5C-B257-568BC3F3EF98Q38686841-D16B686D-2DA8-4FA4-8135-C21FC6413F9DQ38698964-4B235512-B71D-4C7F-8999-0DFF21FB59E2Q38711866-CEBB60E8-154E-47D7-8913-B8E261454D06Q38931269-0C59DC02-AC69-4E3E-AD27-93119A00C021Q38961755-4C2CDDC4-1AF5-453E-A445-CF0CA29A6CBEQ39038214-DA030E38-27F0-499F-8451-D52A4C95746FQ39095194-186BC9AD-CE46-47F2-9E93-1DBB82BDFCBFQ39425380-8E71EB7C-3DC5-40F7-BE21-A4FF01A77E30Q41447434-0E2094A7-B2D3-4FB9-A9ED-3495EC112CCCQ41688145-8E95D449-FDF0-470B-915D-7FC871C0B581Q41991580-E0C4A393-D750-4F41-A57A-43850B0996CFQ42067472-48060FC6-2ACB-49C0-BC60-36F987B3444CQ42323113-F26185CD-4CCF-4E74-8B87-148129A2E991Q42345959-329A91C7-0124-4AC3-9BDF-84FA0130BEECQ42364404-180B8705-FC85-49FF-903B-6886CBEFBD58Q42367902-B9BFB34A-B322-4610-B20E-F0A2356BC10DQ42370353-C9B55B3B-3C55-42A4-B585-166288389C06Q42379684-158B3844-33BC-402F-8EC2-88943EF253E7Q47193640-CFCDE128-C57E-44A6-B90E-B369C4F205EEQ47252459-A1A3AF4E-A6AE-4AA4-ACC9-E221D0BB0F10Q47261072-6083B87A-0054-4F01-B90C-EF5487EEDAF6Q47269814-85F43E97-C480-4244-8838-154323AE6A12Q47397616-D4A27751-5274-4622-AC86-1FE76FC78ED4
P2860
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Adjuvant sunitinib or sorafeni ...... ed, randomised, phase 3 trial.
@en
type
label
Adjuvant sunitinib or sorafeni ...... ed, randomised, phase 3 trial.
@en
prefLabel
Adjuvant sunitinib or sorafeni ...... ed, randomised, phase 3 trial.
@en
P2093
P2860
P50
P1433
P1476
Adjuvant sunitinib or sorafeni ...... ed, randomised, phase 3 trial.
@en
P2093
Christopher G Wood
Christopher Kane
Igor Puzanov
Janice P Dutcher
Judith Manola
Lynne Wagner
Manish Kohli
Michael B Atkins
Michael Carducci
Michael Jewett
P2860
P304
P356
10.1016/S0140-6736(16)00559-6
P407
P577
2016-03-08T00:00:00Z